BRPI0415625A - uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas - Google Patents

uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas

Info

Publication number
BRPI0415625A
BRPI0415625A BRPI0415625-0A BRPI0415625A BRPI0415625A BR PI0415625 A BRPI0415625 A BR PI0415625A BR PI0415625 A BRPI0415625 A BR PI0415625A BR PI0415625 A BRPI0415625 A BR PI0415625A
Authority
BR
Brazil
Prior art keywords
treatment
hydroxamic
acid halide
halide derivative
neurogenerative diseases
Prior art date
Application number
BRPI0415625-0A
Other languages
English (en)
Inventor
Linda Greensmith
Geoffrey Burnstock
Rudolf Urbanics
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of BRPI0415625A publication Critical patent/BRPI0415625A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE UM DERIVADO DE HALOGENETO DE áCIDO HIDROXìMICO NO TRATAMENTO DE DOENçAS NEURODEGENERATIVAS". A invenção relaciona-se ao uso de uma substância química selecionada a partir do grupo consistindo em cloreto de N-¢2-hidróxi-3-(1piperidinil)-propóxi!-piridina-1-óxido-3-carboximidoíla, os enantiómeros opticamente ativos e as misturas de enantiómeros da mesma e os sais farmaceuticamente aceitáveis dos compostos racêmicos e opticamente ativos na preparação de uma composição farmacêutica para o tratamento ou a prevenção de doenças neurodegenerativas.
BRPI0415625-0A 2003-10-30 2004-10-25 uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas BRPI0415625A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303584A HUP0303584A3 (en) 2003-10-30 2003-10-30 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
PCT/HU2004/000098 WO2005041965A1 (en) 2003-10-30 2004-10-25 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
BRPI0415625A true BRPI0415625A (pt) 2006-12-12

Family

ID=89981738

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415625-0A BRPI0415625A (pt) 2003-10-30 2004-10-25 uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas

Country Status (26)

Country Link
US (3) US20080039497A1 (pt)
EP (2) EP1696922B1 (pt)
JP (1) JP5077997B2 (pt)
KR (1) KR20060103323A (pt)
CN (1) CN1901913A (pt)
AT (1) ATE409038T1 (pt)
AU (1) AU2004285343B2 (pt)
BR (1) BRPI0415625A (pt)
CA (1) CA2544332C (pt)
CY (1) CY1110450T1 (pt)
CZ (1) CZ2006347A3 (pt)
DE (1) DE602004016770D1 (pt)
DK (1) DK1696922T3 (pt)
EA (1) EA011301B1 (pt)
ES (1) ES2314458T3 (pt)
HR (1) HRP20080660T3 (pt)
HU (1) HUP0303584A3 (pt)
IL (1) IL175334A (pt)
NO (1) NO20062401L (pt)
NZ (1) NZ547216A (pt)
PL (1) PL1696922T3 (pt)
PT (1) PT1696922E (pt)
SI (1) SI1696922T1 (pt)
UA (1) UA86782C2 (pt)
WO (1) WO2005041965A1 (pt)
ZA (1) ZA200604376B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514418A (ja) 2002-01-11 2005-05-19 ビオレックス クタトー エス フェイレストェー アールテー． カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
US8540985B2 (en) 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
EP2356988A4 (en) 2008-11-18 2012-05-09 Santen Pharmaceutical Co Ltd THERAPEUTIC FOR CHORIORETINAL DEGENERATION WITH PYRIDINE-3-CARBALDEHYDE O- (PIPERIDIN-1-YL-PROPYL) OXIM DERIVATIVE AS ACTIVE SUBSTANCE
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100534A2 (en) * 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
CN103804309B (zh) * 2012-11-09 2019-08-02 广州喜鹊医药有限公司 一种氯肟类化合物及其制备方法和在制药中的应用
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR20210059796A (ko) * 2016-04-29 2021-05-25 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
DE2651083A1 (de) * 1976-11-09 1978-05-18 Hoechst Ag Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5919796A (en) 1994-05-06 1999-07-06 Biorex Kutato Es Fejleszto Rt. Hydroximic acid derivatives, pharmaceutical compositions containing them, and processes for preparing the same
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
UA64716C2 (en) 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
ITMI20012573A1 (it) 2001-12-06 2003-06-06 D B P Dev Biotechonologica L P Gli acilsalicilati:una nuova classe di induttori di risposta heat shock

Also Published As

Publication number Publication date
AU2004285343B2 (en) 2010-05-13
CA2544332C (en) 2014-09-23
NO20062401L (no) 2006-07-27
EP1696922A1 (en) 2006-09-06
AU2004285343A1 (en) 2005-05-12
EP2020233A2 (en) 2009-02-04
PL1696922T3 (pl) 2009-03-31
ATE409038T1 (de) 2008-10-15
HK1097438A1 (en) 2007-06-29
US20150126551A1 (en) 2015-05-07
ZA200604376B (en) 2009-04-29
HRP20080660T3 (hr) 2009-01-31
US20080039497A1 (en) 2008-02-14
US20120115908A1 (en) 2012-05-10
CN1901913A (zh) 2007-01-24
IL175334A0 (en) 2008-04-13
KR20060103323A (ko) 2006-09-28
HUP0303584A2 (hu) 2005-12-28
EA200600866A1 (ru) 2006-10-27
IL175334A (en) 2010-12-30
CZ2006347A3 (cs) 2006-10-11
DK1696922T3 (da) 2008-12-01
SI1696922T1 (sl) 2008-12-31
HUP0303584A3 (en) 2009-12-28
US8962604B2 (en) 2015-02-24
PT1696922E (pt) 2008-10-17
JP5077997B2 (ja) 2012-11-21
DE602004016770D1 (de) 2008-11-06
CA2544332A1 (en) 2005-05-12
EA011301B1 (ru) 2009-02-27
ES2314458T3 (es) 2009-03-16
CY1110450T1 (el) 2015-04-29
EP2020233A3 (en) 2009-09-30
HU0303584D0 (en) 2003-12-29
WO2005041965A1 (en) 2005-05-12
EP1696922B1 (en) 2008-09-24
JP2007509920A (ja) 2007-04-19
NZ547216A (en) 2009-03-31
UA86782C2 (ru) 2009-05-25

Similar Documents

Publication Publication Date Title
BRPI0415625A (pt) uso de um derivado de halogeneto de ácido hidroxìmico no tratamento de hidroxìmico no tratamento de doenças neurogenerativas
BR0215777A (pt) Composto, método para preparar o mesmo, composição farmacêutica para prevenir e tratar cardioisquemia, cerebroisquemia, oclusão arterial cerebral e para melhorar microcirculação do cérebro, e uso do composto
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BR0210384A (pt) Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BRPI0416283A (pt) compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
BR0113755A (pt) Composto multimérico, processo para a preparação de composto, composição farmacêutica que compreende o composto, processo para o tratamento e/ou profilaxia e detecção de uma infecção por virus, utilização do composto, e inalador que contém a composição
BR0312000A (pt) Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BRPI0417714A (pt) composto, composição farmacêutica, e, uso de um composto
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
BR0109430A (pt) Derivados amidoxima de ácido propenocarboxìlico, processo para a preparação dos mesmos, e composições farmacêuticas que contêm os mesmos
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR0315106A (pt) Derivados antimicrobianos de [3.1.0]oxazolidinona bicìclica
BRPI0512951A (pt) compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha)
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
BR0315400A (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente e para inibir o crescimento de uma célula de câncer ou célula neoplástica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ORPHAZYME APS (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ORPHAZYME A/S (DK)